Data from GNT-018-IDES Trial Supports Feasibility of imlifidase as Pretreatment in Gene Therapy Treatment for Patients With Crigler–Najjar Syndrome Who Are Immune to AAV

Results presented today at ESGCT 2025 PARIS–(BUSINESS WIRE)–Genethon, a worldwide pioneer and leader in research and development of gene therapy for rare genetic diseases, and Hansa Biopharma, a Sweden-based leader in IgG cleaving enzyme technology announced today that a patient with a rare liver disease and immunity to the AAV vector has been successfully treated … [Read more…]

Data Analyses Show Benefit for Individuals With Infantile-Onset Niemann-Pick Disease Type C Treated With Investigational Drug Adrabetadex

Analysis shows statistically significant survival benefit in individuals with infantile-onset Niemann-Pick disease type C (NPC) treated with adrabetadex compared to matched external controls Findings from an analysis of key biomarkers support the disease-modifying potential of adrabetadex in individuals with NPC THOUSAND OAKS, Calif.–(BUSINESS WIRE)–Mandos Health® by Beren Therapeutics Public Benefit Corporation (P.B.C.) announced today that … [Read more…]

Lumina 3D by RapidAI Named to TIME’s List of the Best Inventions of 2025

AI-driven 3D imaging breakthrough recognized among the year’s most transformative innovations SAN MATEO, Calif.–(BUSINESS WIRE)–RapidAI, the pioneer of deep clinical AI and the global leader in image-based decision support and workflow efficiencies, today announced that its Lumina 3D™ built on the Rapid Enterprise™ Platform has been named to TIME’s List of the Best Inventions of … [Read more…]

bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

SAN ANTONIO–(BUSINESS WIRE)–#BIAF—bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced it has closed the previously announced definitive agreements for the purchase and sale of 720,000 shares of common stock at a purchase price of $2.50 per share in a … [Read more…]

Modus Create Appoints Sharon Lynch as Chief Executive Officer

RESTON, Va.–(BUSINESS WIRE)–Modus Create, a global leader in digital product engineering, today announced the appointment of Sharon Lynch as Chief Executive Officer (CEO). Lynch succeeds Pat Sheridan, co-founder of Modus Create, who will transition to the role of Chairman. Lynch brings a proven track record of helping organizations innovate, scale, and thrive in rapidly evolving … [Read more…]

MindWalk Announces Share Repurchase Program

AUSTIN, Texas–(BUSINESS WIRE)–$hyft #AI–MindWalk Holdings Corp. (“MindWalk” or the “Company”) (NASDAQ: “HYFT”), a bio-native AI company, today announced that to underscore its confidence in MindWalk’s future development and growth prospects, its Board of Directors (the “Board”) has authorized a share repurchase program under which MindWalk may repurchase up to 2.3 million common shares of the … [Read more…]

The Institute of Clinical Research Launches New Company Membership Scheme to Support Clinical Research Professionals

LONDON–(BUSINESS WIRE)–#CRO–The Institute of Clinical Research (The ICR) is delighted to announce the launch of its Company Membership Scheme, an initiative designed to strengthen professional development and collaboration across the clinical research sector by increasing access to the clinical research community to a wider membership. Several organisations have already joined as Company Members, demonstrating strong … [Read more…]

Navidea Biopharmaceuticals, Inc. Files for Bankruptcy

Navidea Biopharmaceucitals, Inc. files for Bankruptcy COLUMBUS, Ohio–(BUSINESS WIRE)–Navidea Biopharmaceuticals, Inc. (“Navidea” or the “Company”), a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it filed a voluntary petition for relief under Chapter 11, Subchapter V of the United States Bankruptcy Code in the U.S. Bankruptcy Court for … [Read more…]

Raman Bhaumik to Represent Thesis Pharmacy at A4M Longevity Fest 2025

The American Academy of Anti-Aging Medicine’s flagship event will feature Thesis Pharmacy, represented by licensed pharmacist and healthcare leader Raman Bhaumik. PLANO, Texas–(BUSINESS WIRE)–Raman Bhaumik, an entrepreneur and licensed pharmacist, will represent Thesis Pharmacy at A4M’s Longevity Fest 2025, held December 12–14, 2025, at The Venetian and Palazzo Resort in Las Vegas. The event, hosted … [Read more…]

Philip Morris International Urges U.S. Food and Drug Administration Advisory Committee to Recommend Continued Marketing of IQOS as Modified Risk Product

A pioneer in modified risk tobacco products, Philip Morris International is the only company to have received a modified risk marketing claim for an electronic nicotine device. FDA concludes “Evidence continues to support the modified exposure claim that ‘Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduces your … [Read more…]